Business Model Breakdown
How IDEAYA Biosciences Inc Makes Money
IDYA
Market Cap
$2.9B
Profit Margin
0.0%
Employees
131
The Short Version
IDEAYA Biosciences is a biotechnology company focused on the discovery and development of precision medicines for cancer, primarily using synthetic lethality. This innovative approach targets cancer cells by exploiting specific genetic vulnerabilities, leaving healthy cells unharmed. The company generates revenue through strategic collaborations with larger pharmaceutical companies, which provide upfront payments, research funding, and potential milestone payments and royalties on future sales. Eventually, if its drugs are approved, it would generate revenue from product sales, either independently or through its partners, aiming to address significant unmet medical needs in oncology.
Where the Revenue Comes From
Collaboration and license revenue (from partnerships like GSK, AstraZeneca)
Potential future product sales (post-regulatory approval and commercialization)
Who buys: Primarily cancer patients through healthcare providers/oncologists, and pharmaceutical partners.
Why It Works (Competitive Advantages)
- ✔Proprietary synthetic lethality platform and extensive intellectual property.
- ✔Strategic partnerships with leading pharmaceutical companies (GSK, AstraZeneca) providing validation and funding.
- ✔Diversified pipeline targeting multiple difficult-to-treat cancers.
Economic Moat: Narrow (Intangible Assets/IP (proprietary drug candidates and target identification platform), Switching Costs (once approved and adopted by physicians/patients, but post-commercialization), Partnerships (long-term collaborations with major pharma validating and extending reach))
What Our Analysis Says
DVR Score as of April 11, 2026
IDEAYA Biosciences maintains a strong score, reflecting its pioneering role in synthetic lethality oncology, a field with immense unmet needs and significant market potential for 10x growth. The robust GSK and recent AstraZeneca partnerships validate its platform, providing critical non-dilutive funding and extending cash runway, which is vital for an early-stage biotech. The imminent topline results from the Phase 2/3 OptimUM-02 trial on April 13, 2026, for darovasertib in uveal melanoma, is a highly anticipated and primary re-rating catalyst. While the company is pre-revenue with inherent biotech clinical and financial risks (with specific financial metrics not available from the provided data), its strategic positioning, diversified pipeline, and approaching catalysts underpin its high potential for substantial growth. Continued execution on clinical milestones and partnerships reinforce the bullish thesis.